The Protein Myth: Our Obsession With Protein and How It Is Killing US

Houston Methodist

G. Davis

Primer on Diabetes Management

Symposium on Diabetes and Cancer 2017: Novel Links and Treatments

S. Inzucchi

Heart Failure in Women: 2025 Update

Scripps Health

M. Kittleson

Health of Vegetarians and Vegans: Findings From EPIC-Oxford and Othe…

Physicians Committee for Responsible Medicine

T. J. Key

Medications for Weight Loss: The New Satiety Hormones

Scripps Health

K. Fujioka

The GOOD and the BAD Side of GLP-1s and What to Do If You Get Caught…

Endocrinology 2024 Year in Review

Weightloss in Menopause

Susan Brian

Do Triglycerides Cause Heart Disease?

National Lipid Association

I. Goldberg

Diabetes Treatment Guidelines Finally Have Entered the 21st Century …

ASPC 2019 Congress on CVD Prevention

R. DeFronzo

Is There a Future for HbA1c? (Moving Towards CGM: GMI and TIR)

Practical Ways to Achieve Targets in Diabetes Care

I. Hirsch

Evidence that Obesity and Diabetes are Driven by a Diet-Induced Biol…

University of Colorado Department of Medicine

R. Johnson

SURPASS 2: Tirzepatide Versus Once-Weekly Semaglutide

Juan Frias

Labs to Check on Semaglutide or Tirzepatide

Susan Brian

ADA-KDIGO Consensus Report on Diabetes Management in CKD - More Alik…

KDIGO

C. Rhee

MAFLD: What Is It?

Houston Methodist

D. Victor

Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibiti…

Cardiology Fiesta 2017

R. DeFronzo

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

Cardiometabolic Health Congress (CMHC)

L. Sloan

SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease

Rita Jermyn

Tirzepatide Updates

Diana Isaacs